Translational Neuroscience Optimization of GlyT1 Inhibitor
Status: | Recruiting |
---|---|
Conditions: | Cognitive Studies, Schizophrenia |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 21 - 65 |
Updated: | 10/10/2018 |
Start Date: | August 2013 |
End Date: | January 2019 |
Contact: | Emma Deaso, BA |
Email: | emma.deaso@yale.edu |
Phone: | 203-974-7489 |
This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of
stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this
study is to test the efficacy of treatment with one of two does of a glycine transporter
inhibitor (GlyT1I) combined with cognitive remediation to enhavce cognitive function.
Subjects will be randomized to one of two doses of the glycine transporter inhibitor (GlyT1I)
and placebo twice daily in addition to their antipsychotic medication for 2 treatment
periods, each lasting a minimum of 5 weeks. Treatment periods will be separated by a washout
period lasting approximately 3 weeks.
stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this
study is to test the efficacy of treatment with one of two does of a glycine transporter
inhibitor (GlyT1I) combined with cognitive remediation to enhavce cognitive function.
Subjects will be randomized to one of two doses of the glycine transporter inhibitor (GlyT1I)
and placebo twice daily in addition to their antipsychotic medication for 2 treatment
periods, each lasting a minimum of 5 weeks. Treatment periods will be separated by a washout
period lasting approximately 3 weeks.
Inclusion Criteria:
- 1) Males or females 21 to 65 years of age (inclusive).
- 2) Diagnosis of Schizophrenia or Schizoaffective Disorder
- 3) Able to provide written informed consent.
- 4) Only CYP2D6 extensive metabolizers.
Exclusion Criteria:
- 1) No ongoing acute medical issues
- 2) Clinically significant ECG abnormality
- 3) Blood donation within eight weeks of the start of the study
- 4) Current treatment with Clozapine
We found this trial at
2
sites
950 Campbell Ave
West Haven, Connecticut 06516
West Haven, Connecticut 06516
(203) 932-5711
Principal Investigator: Deepak C D'Souza, MD
Phone: 203-932-5711
VA Connecticut Healthcare System VA Connecticut encompasses an inpatient facility and Ambulatory Care Center in...
Click here to add this to my saved trials
New Haven, Connecticut 06508
Principal Investigator: Deepak C D'Souza, MD
Phone: 203-974-7489
Click here to add this to my saved trials